Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 7, No 1 (2014) PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY Abstract  similar documents
D. V. Blinov
"... weeks; babies with the intra-ventricular hemorrhages (IVH group) and periventricular leukomalacia (PVL ..."
 
Vol 11, No 2 (2018) Regional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations Abstract  similar documents
M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov
"... The existing model of financial support of medical assistance for clinical-statistical groups (CSGs ..."
 
Vol 10, No 4 (2017) THE STATE GUARANTEES PROGRAM OF FREE MEDICAL CARE: APPROACHES TO STANDARDIZE THE COSTS OF MEDICAL CARE Abstract  similar documents
Yu. A. Ledovskikh, E. V. Semakova, M. V. Avksent’eva
"... and statistical groups. ..."
 
Vol 11, No 2 (2018) Introduction of medical products into healthcare practice and costs reimbursement: European experience Abstract  similar documents
V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii
 
Vol 7, No 1 (2014) ECONOMIC ASSESSMENT OF MAGNESIUM DEFICIENCY CORRECTION FOR BASIC THERAPY EFFICACY OF UNCONTROLLED ASTHMA IN CHILDREN Abstract  similar documents
V. I. Petrov, I. N. Shishimorov, O. V. Magnitskaya, Ju. V. Ponomareva
"... the cost of achieving control and cost per symptom-free day after 12 and 24 weeks of therapy. ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... of randomized controlled trials (RCT) and indirect RCT comparison. The expenditures for drugs of TRA group ..."
 
Vol 8, No 2 (2015) MAGNESIUM DEFICIENCY OF PATIENTS WITH HORMONE DEPENDENT DISEASES: PHARMACOEPIDEMIOLOGICAL PROFILE AND LIFE QUALITY ASSESSMENT Abstract  similar documents
Dmitry Vladislavovich Blinov, Juliana Vladimirovna Zimovina, Elena Anatol'evna Sandakova, Tat'yana Igorevna Ushakova
"... as well as quality of life questionnaire the World Health Organization WHOQOL-BREF after 4 weeks therapy ..."
 
Vol 7, No 2 (2014) MANAGEMENT OF MAGNESIUM DEFICIENCY IN PREGNANT WOMEN: PHARMACOEPIDEMIOLOGIC STUDY Abstract  similar documents
D. V. Blinov, U. V. Zimovina, E. M. Dzhobava
"... collected at Visit 1 and visit 2 (1 month +/- 1 week): complete medical history; diagnosis of Mg deficiency ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... weeks was lower with ocrelizumab than that with interferon β-1a (0.16 vs. 0.29, 47% decrease, p<0 ..."
 
Vol 7, No 4 (2014) MODELING IN CLINICO-ECONOMIC ANALYSIS OF MEDICAL ORGANIZATIONAL TECHNOLOGIES Abstract  similar documents
M. A. Shapovalova, A. R. Umerova, V. A. Bondarev, L. R. Koretskaya
"... : the patient in the treatment of neurological hospital in the treatment of a patient in a neurological hospital ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Abstract  similar documents
A. U. Kulikov, I. A. Komarov
"... of this group of patients. We performed budget impact analysis on the basis of two bronchodilators in Russian ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... contributes to the improvement of approaches to treatment policy of this group of patients. We performed cost ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET Abstract  similar documents
R. I. Yagudina, V. G. Serpik
"... weeks of the first year of treatment for a combination of Mimpara, vitamin E and drugs phosphorbinders ..."
 
Vol 7, No 1 (2014) ABC END VEN ANALYSYS OF COSTS FOR MEDICINE SAND MEDICAL TREATMENT COSTS PATIENT Abstract  similar documents
M. A. Shapovalova, L. R. Koretskaya
"... Abstract: for a detailed assessment of neurological patients to assist non-governmental agencies ..."
 
Vol 9, No 4 (2016) ФАРМАКОЭКОНОМИЧЕСКИЙ АНАЛИЗ ПРИМЕНЕНИЯ КОМБИНАЦИИ ОЛМЕСАРТАН/ЛЕРКАНИДИПИН И ЗОФЕНОПРИЛ/ЛЕРКАНИДИПИН В ЛЕЧЕНИИ ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ Abstract  similar documents
"... стоимость снижения АД на 1 мм рт.ст. была самой наименьшей в группе Зофеноприл/Лерканидипин. Заключение. По ..."
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
"... created a “decision tree” model that allowed us to calculate the costs of 48-week insulin therapy in 1000 ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... of two group. Patients of the first (main) group received a course of intraosseous blockades, while ..."
 
Vol 8, No 2 (2015) CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA Abstract  similar documents
Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova
"... divided into 4 groups depending on their therapy. The period of observation was 12 months. The 1st group ..."
 
Vol 9, No 1 (2016) REVIEW OF HEALTH SYSTEM ORGANIZATION APPROACHES TO ESTIMATING SERVICE LEVELS AND EXPENDITURES FOR INPATIENT CARE SERVICES Abstract  similar documents
K. V. Gerasimova, D. V. Fedyaev, M. V. Sura, A. A. Tikhonova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... is based on per case of treatment for a relevant group of diseases (diagnosis related group (DRG ..."
 
Vol 11, No 2 (2018) Clinical and economic efficiency of the loop ileostomy closure by various methods Abstract  similar documents
A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov
"... and methods. The study included 327 patients randomized into 3 groups. in group 1, the closure of an ileostomy ..."
 
Vol 10, No 1 (2017) CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS Abstract  similar documents
P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova
"... with the given drug, was 53% in the eribulin group, and 18% in the trabectedin group. The total number ..."
 
Vol 5, No 2 (2012) WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM Abstract  similar documents
A. I. Borodin
"... necessity of working out the scientifically-proved strategy of storekeeping by different groups of medicines ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... the schemes of antiretroviral therapy as compared to the schemes on the basis of drugs from the group ..."
 
Vol 7, No 1 (2014) CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT Abstract  similar documents
I. I. Shteynberg, S. K. Zyryanov, Yu. B. Belousov
"... groups according to the therapy (imipenem, meropenem, doripenem). There were no statistically significant ..."
 
Vol 8, No 4 (2015) ABC-, VEN и частотный анализ терапии фибрилляции предсердий в условиях «типичной практики» Abstract  similar documents
"... использования лекарственных средств в поликлинике выявлено, что процентный объем препаратов между группами в ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... биологическими препаратами из группы ингибиторов ФНО-α внедрение ведолизумаба у взрослых пациентов со ..."
 
Vol 8, No 4 (2015) PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER Abstract  similar documents
D. A. Zhukov
"... observation groups was calculated using the Pearson χ2 criterion (with Bonferroni correction, if needed ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... (Sintez) was the most effective antibiotic of the cephalosporin group in the treatment of acute ..."
 
Vol 7, No 2 (2014) THE ANALYSIS OF THE LIPETSK PHARMACEUTICAL MARKET OF NASAL GLUCOCORTICOSTEROID Abstract  similar documents
K. V. Danilova, I. M. Razdorskaya
"... in the present paper we have studied a group of pharmaceutical drugs used in the treatment ..."
 
Vol 7, No 1 (2014) PHARMACOEPIDEMIOLOGY: FROM THEORY TO PRACTICE Abstract  similar documents
S. A. Rachina, R. S. Kozlov, Yu. A. Belkova
"... the use of and the effects of drugs in the whole population or in large groups of people in order ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS Abstract  similar documents
E. E. Vidyakina, S. V. Malchikova
"... analysis show that the percentage correlation of medicines of different groups generally corresponds ..."
 
Vol 7, No 3 (2014) PROBLEMS OF OUTCOMES CHOICE FOR THE ASSESSMENT OF REHABILITATION PROGRAMS EFFICIENCY IN PATIENTS AFTER STROKE AND CRANIOCEREBRAL INJURY Abstract  similar documents
V. S. Dombrovskiy, V. V. Omelyanovskiy
"... significant discrepancy between the patient's status characteristics. Thus, in the disability group I only 7 ..."
 
Vol 11, No 2 (2018) Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer Abstract  similar documents
G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin
"... a combined treatment. Of these, 120 patients (study group) received hypofractionated radiotherapy (40.5 Gy ..."
 
Vol 11, No 3 (2018) What is the role of antineoplastic drug safety in reimbursement decision making? Abstract  similar documents
A. S. Kolbin, A. A. Kurylev
"... to reimbursement in Russia has grown from 15% to 28%. This group of drugs is characterized by severe adverse events ..."
 
Vol 8, No 2 (2015) REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS Abstract  similar documents
Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev
"... mechanisms for vulnerable social groups, national cost-sharing models are considered. ..."
 
Vol 6, No 3 (2013) THE ANALYSIS OF THE MARKET OF PHARMACEUTICALS FOR DYSMENORRHEA TREATMENT Abstract  similar documents
N. Yu. Cherkasova, A. V. Fomina, O. V. Filippova
"... of Russian Federation was carried out. Various groups of medicaments can be used for the dysmenorrhea therapy ..."
 
Vol 8, No 2 (2015) PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS Abstract  similar documents
Anton Alexandrovich Kasatkin
"... costs for this group of patients depends on the severity of the injury and the amount of blood loss ..."
 
Vol 9, No 4 (2016) PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION Abstract  similar documents
D. S. Kaskaeva, M. M. Petrova, O. V. Zimnitskaya
"... Hg was the smallest in the group zofenopril/lercanidipine. Conclusion. The results ..."
 
Vol 9, No 4 (2016) PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION Abstract  similar documents
D. S. Kaskaeva, M. M. Petrova, O. V. Zimnitskaya
"... Hg was the smallest in the group zofenopril/lercanidipine. Conclusion. The results ..."
 
Vol 10, No 4 (2017) INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW Abstract  similar documents
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova
"... the reference group of drugs. However, today’s control of biosimilar pricing in Europe is just building up ..."
 
Vol 10, No 4 (2017) INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW Abstract  similar documents
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova
"... the reference group of drugs. However, today’s control of biosimilar pricing in Europe is just building up ..."
 
Vol 11, No 3 (2018) Use of medications in children hospitalized with community-acquired pneumonia Abstract  similar documents
D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova
"... .22%). Specifically, the greatest contribution was made by the J01D group «Beta-lactam antibacterial drugs, other» (64 ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... лираглутида (0,6 мг, 1,2 мг и 1,8 мг в сутки). Продолжительность всех исследований составляла 26 недель ..."
 
Vol 9, No 1 (2016) SYSTEMATIC REVIEW OF PENTAGLOBIN EFFICACY IN PREVENTING MORTALITY IN NEWBORNS AND OLDER CHILDREN WITH BACTERIAL INFECTIONS AND SEPSIS Abstract  similar documents
V. K. Fedyaeva, O. Yu. Rebrova
"... groups, RR 0.51 [0.32; 0.82], and in BT with or without placebo, RR 0.56 [0.34; 0.91]. Children under 24 ..."
 
1 - 50 of 168 Items 1 2 3 4 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)